Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twelve ...

In a report released yesterday, Jason Zemansky from Bank of America Securities reiterated a Buy rating on Travere Therapeutics (TVTX – ...

The US Food and Drug Administration (FDA) has converted the accelerated approval for Travere Therapeutics’ Filspari ...

Data presentations highlight the results for FILSPARI®(sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as ...

Travere Therapeutics specializes in rare kidney and metabolic disease treatments with key drugs Filspari and Thiola. Filspari, a key asset for IgA Nephropathy, has received full FDA approval ...

Shortly after winning full FDA approval for its rare kidney disease drug Filspari, San Diego’s Travere Therapeutics has run into trouble with its enzyme replacement candidate pegtibatinase.

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on ...

Travere Therapeutics has implemented a 20% reduction of its workforce to funnel resources into Filspari’s (sparsentan) launch in IgA nephropathy (IgAN) and the clinical development of pegtibatinase.

Shares of Travere Therapeutics moved higher after the biopharmaceutical company said it won full Food and Drug Administration approval of its kidney-disease drug Filspari. Travere shares were ...

Travere Therapeutics Inc (TVTX) reports a 77% increase in net product sales, driven by FILSPARI's performance, while ...

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...